Navigation Links
Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society's Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
Date:11/4/2008

JERUSALEM, November 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of proprietary drug delivery systems, announced today that its poster entitled "Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs," has been accepted for presentation at the Diabetes Technology Society's Eighth Annual Meeting in Bethesda, Maryland between November 13-15, 2008.

Oramed's exploratory study of enteral delivery of GLP-1 analog, exenatide-4, an incretin mimetic with antihyperglycemic actions on dogs, advances research in the area of enteral delivery of polypeptides and proteins. Oramed's test results showed that direct instillation of GLP-1 analog significantly curbed post-glucose loading, demonstrating the feasibility of administering the drug enterally.

"The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a wonderful opportunity for us to demonstrate our revolutionary technology to the world's leading diabetes scientists," said Nadav Kidron, Oramed CEO. "We are very proud that our research is advancing the treatment of diabetes and we look forward to continuing to present strong results from the studies and trials we are currently conducting."

Oramed's abstract will be presented on Thursday, November 13, from 6-8 PM. The poster will be available for viewing throughout the conference.

For more information about the Diabetes Technology Society's Eighth Annual Meeting, please visit http://www.diabetestechnology.org/index.html

For more information about Oramed Pharmaceuticals, please visit http//www.oramed.com

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
2. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
3. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
7. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
8. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
9. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
10. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
11. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... on Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") ... of Directors ("Depomed Board") set a record date to ... The Depomed Board will review the ... is received today and contains the information required under ...
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... development portfolio building on lead product ... Phase 2 trial for onychomycosis, WELLESLEY HILLS, Mass., ... announced that it has,exercised the option it acquired in ... uses of pexiganan, a novel, small peptide,anti-infective for treatment ...
... BOULDER, Colo., Oct. 3 Tapestry,Pharmaceuticals, Inc. (Nasdaq: ... 2 open- label, multi-center study of TPI 287 in ... 2 trial exploring the,activity of TPI 287 in various ... year in advanced hormone refractory prostate cancer. "Currently ...
Cached Medicine Technology:MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 2MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 3MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 4MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 5MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 6Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 2Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 3Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 4Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 5
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... ... 04, 2015 , ... The Law Offices of Ben C. Martin , ... with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter lawyer for ... Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices and ...
(Date:8/4/2015)... Louis, MO (PRWEB) , ... August 04, 2015 ... ... attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report that ... Talcum powder lawyers provide regular news updates and cancer warning information ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing ... in support of an interaction simulation session entitled "NOACS: What the Evidence Shows ... by Medical Learning Institute Inc. and EDUmotion US LLC. , This special activity ...
(Date:8/4/2015)... ... 2015 , ... Lightning Labels is pleased to announce the ... usher in a new standard of sticker and label-making for the company. , ... twin objectives of quality and quantity without compromising the signature lightning-fast speed we ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3
... Medical University ... epidural prefrontal cortical stimulation , CHARLESTON, S.C., Oct. 13 ... with treatment-resistant depression. Bilateral epidural prefrontal cortical stimulation (EpCS) was ... in a small group of patients, according to lead researcher ...
... Package Continues to Provide Daily Requirement of Milk and ... The following was issued today by the Dairy Council ... available to WIC participants has garnered public attention, it ... continue to be strongly supported nutrient-rich options in this ...
... October marks Domestic Violence Awareness month and on October ... professionals across the country will reflect on over 800 ... restored by the American Academy of Cosmetic Dentistry Charitable ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091013/DC91525 ) , ...
... invasive procedures (including the use of robotic assistance) for ... may shorten hospital stays and decrease respiratory and surgical ... of certain complications, including incontinence and erectile dysfunction, according ... JAMA , a theme issue on surgical care. ...
... 13, 2009 Early action, especially rapid rollout of vaccines, ... H1N1 influenza virus, according to a simulation model of a ... CMAJ ( Canadian Medical Association Journal ) ... that projects how many people will be infected under different ...
... finds better short-term results for endovascular repair than for ... A less-invasive method of abdominal aortic aneurysm (AAA) repair ... new U.S. study. , The interim findings are from ... and open surgical repair of AAA. The report included ...
Cached Medicine News:Health News:New Brain Stimulation Treatment May Offer Hope For Those With Treatment Resistant Depression 2Health News:New Brain Stimulation Treatment May Offer Hope For Those With Treatment Resistant Depression 3Health News:With All the Focus on What's New, Milk Remains Tried and True 2Health News:Over 800 Lives of Domestic Violence Survivors Restored by the American Academy of Cosmetic Dentistry Charitable Foundation's Give Back A Smile Program 2Health News:Minimally invasive radical prostatectomy shows advantages, but also certain complications 2Health News:H1N1 simulation modeling shows rapid vaccine rollout effective in reducing infection rates 2Health News:Study Compares Abdominal Aortic Aneurysm Repair Methods 2
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Active Cath is a latex, self-adhering, one piece catheter designed for extended wear. It combines a shortened latex sheath with a wide adhesive seal....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Medicine Products: